Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial
Alexandra Gilbert(St James's University Hospital), Max Whibley(Royal Sussex County Hospital), Andrew G. Renehan(University of Manchester), Lindy Berkman, Natalie L. Abbott(St Bartholomew's Hospital), Shaharyar M. Khan(Royal Sussex County Hospital), Richard Adams(Velindre Cancer Centre), Henry M. Wood(University of Leeds), Joanne Copeland(University of Leeds), M. Hawkins(University College Hospital), Susan D. Richman(University of Leeds), David Sebag‐Montefiore(University of Leeds), Rob Glynne‐Jones(Mount Vernon Cancer Centre), Vicky Goh(King's College London), Sarah Brown(University of Leeds), Duncan C. Gilbert(Royal Sussex County Hospital), Daniel Bottomley(University of Leeds), Alexandra Stewart(Royal Surrey County Hospital), Sheela Rao(Royal Marsden NHS Foundation Trust), Sharon Ruddock(University of Leeds), Joanne Webster(University of Leeds), Alexandra Smith(University of Leeds), Mark Harrison(Hillingdon Hospitals NHS Foundation Trust), Stephen A. Falk(At Bristol), R. Muirhead(Churchill Hospital)
Cited by 23
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k